Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the Australian Patent Office has granted Canntab an Australian Patent related to its proprietary cannabidiol formulations.
Goldstein talks about another validation of their technology with this patent and also the fact they have a purchase order from Australia. Goldstein also told Proactive the company will be taking part in Australia's Largest Observational Medical Cannabis Research Study ever.